Recombinant Human TIGIT Protein，His

TIGIT (T cell immunoreceptor with Ig and ITIM domains) is an immune checkpoint receptor primarily expressed on T cells and natural killer (NK) cells. It plays a critical role in regulating immune responses and maintaining self-tolerance by inhibiting T cell activation and promoting immunosuppressive environments, particularly in cancer and chronic infections. The study of TIGIT has gained significant attention due to its potential as a therapeutic target in cancer immunotherapy. In tumors, TIGIT can be upregulated, leading to immune evasion and diminished anti-tumor activity. Research into TIGIT has revealed that it interacts with its ligands, such as CD155 and CD112, which are often overexpressed in tumor microenvironments. This receptor-ligand interaction triggers inhibitory signaling pathways that dampen the immune response. Consequently, the development of TIGIT as a recombinant protein for therapeutic applications is being explored to block its inhibitory function, thereby reinvigorating T cell and NK cell activity against tumors. Various studies are underway to assess the efficacy and safety of TIGIT-targeted therapies, either as monotherapies or in combination with existing immune checkpoint inhibitors like PD-1/PD-L1 therapies. These investigations are crucial in advancing our understanding of TIGIT's role in immune regulation and its potential to enhance anti-tumor immunity, making it a promising candidate in the evolving landscape of cancer immunotherapy.